| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, New Haven, Connecticut
Department of Veterans Affairs Medical Center, West Haven, Connecticut
Research Biochemicals International, Natick, Massachusetts
Correspondence: For correspondence or reprints contact: John P. Seibyl, MD, Section of Nuclear Medicine, TE-2, Department of Diagnostic Radiology. Yale University School of Medicine, 333 Cedar St., New Haven, CT 06510.
ABSTRACT
Iodine-123-ß-CIT has been used as a probe of monoamine transporters in human and nonhuman primates utilizing SPECT. To assess the utility of this tracer for measurement of striatal dopamine (DA) transporters in human disease, we studied the test/retest variability and reliability of SPECT measures obtained after bolus injection of [123I]ß CIT 0–7 hr (Day 1) and 18–24 hr (Day 2) after administration. Methods: For the Day 2 study, seven healthy humans (4 men, 3 women; aged 19–74 yr) participated in two [123I]ß-CIT SPECT scans separated by 7–14 days. Subjects were imaged at 18, 21 and 24 hr post injection of 370 MBq (10 mCi) [123I]ß-CIT. Two outcome measures were evaluated:(a) the ratio of specific striatal (activity associated with DA transporter binding) to nondisplaceable uptake, also designated V''3 and (b) the total specific striatal uptake (%SSU) expressed as a percentage of injected radiotracer dose. Test/retest variability associated with V''3 and total specific striatal uptakes were compared for scans acquired at 18, 21 and 24 hr with 24 hr only postinjection scans. For the Day 1 study, three of the subjects participated in two kinetic studies of [123I]ß-CIT uptake. A three-compartment model was used for determination of konBmax and binding potential (BP = Bmax/Kd) and the reproducibility of the measures assessed. Results: In the Day 2 study, both outcome measures demonstrated excellent test/retest reproducibility with variability of V''3 = 6.8 ± 6.8% and percent striatal uptake = 6.6 ± 4.3% using data acquired from all time points. There were no significant differences in variability for the two outcome measures obtained. The intraclass correlation coefficient 
was 0.96 and 0.98 for V''3 and %SSU, respectively. Considering the 24 hr postinjection scans only, there was a nonsignificant trend toward lower test/retest variability for %SSU compared to V''3 (6.6 ± 42% and 12.8 ± 9.0%, respectively). The test/retest variability for the Day 1 kinetic modeling data showed marked differences depending on the fitting strategy and assumptions about the reversibility of [123I]ß-CIT in striatum. Using a model that assumed a low, fixed value for reversible striatal binding(kM4) produced low variability (12 ± 9%). Conclusion: These data suggest that SPECT imaging performed at either 0–7 hr or 18–24 hr after [123I]ß-CIT injection permits calculation of reliable and reproducible measures of dopamine transporters and supports the feasibility of using [123I]ß-CIT in serial evaluation of human neuropsychiatric disease.
Key Words: iodine-123-ß-CIT • SPECT • dopamine transporter
This article has been cited by other articles:
|
|
 |
|
  A. M. Catafau, M. Danus, S. Bullich, J. Llop, J. Perich, V. J. Cunningham, P. Plaza, M. M. Penengo, J. L.H. Eersels, L. Squassante, et al. Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 1--Pseudoequilibrium Interval and Quantification Methods J. Nucl. Med., June 1, 2006; 47(6): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Catafau, V. Perez, M. M. Penengo, S. Bullich, M. Danus, D. Puigdemont, J. C. Pascual, I. Corripio, J. Llop, J. Perich, et al. SPECT of Serotonin Transporters Using 123I-ADAM: Optimal Imaging Time After Bolus Injection and Long-Term Test-Retest in Healthy Volunteers J. Nucl. Med., August 1, 2005; 46(8): 1301 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koch, P. E. Radau, C. Hamann, and K. Tatsch Clinical Testing of an Optimized Software Solution for an Automated, Observer-Independent Evaluation of Dopamine Transporter SPECT Studies J. Nucl. Med., July 1, 2005; 46(7): 1109 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. van Dyck, R. T. Malison, L. K. Jacobsen, J. P. Seibyl, J. K. Staley, M. Laruelle, R. M. Baldwin, R. B. Innis, and J. Gelernter Increased Dopamine Transporter Availability Associated with the 9-Repeat Allele of the SLC6A3 Gene J. Nucl. Med., May 1, 2005; 46(5): 745 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Hwang, W. J. Yao, S. P. Wey, and G. Ting Reproducibility of 99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson's Disease J. Nucl. Med., February 1, 2004; 45(2): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Davis, J. R. Votaw, J. D. Bremner, M. G. Byas-Smith, T. L. Faber, R. J. Voll, J. M. Hoffman, S. T. Grafton, C. D. Kilts, and M. M. Goodman Initial Human PET Imaging Studies with the Dopamine Transporter Ligand 18F-FECNT J. Nucl. Med., June 1, 2003; 44(6): 855 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Marek, R. Innis, C. van Dyck, B. Fussell, M. Early;, S. Eberly, D. Oakes, and J. Seibyl [123I]{beta}-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology, December 11, 2001; 57(11): 2089 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. J. Laine, A. Ahonen, P. Rasanen, T. Pohjalainen, J. Tiihonen, and J. Hietala The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics Alcohol Alcohol., May 1, 2001; 36(3): 262 - 265. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
